BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-241@pharmaconomics
DTSTAMP:20260707T034448Z
DTSTART;VALUE=DATE:20260328
DTEND;VALUE=DATE:20260329
SUMMARY:RCKT PDUFA — KRESLADI
DESCRIPTION:The FDA's approval decision on KRESLADI for severe leukocyte adhesion deficiency-I (LAD-I) is due Mar 28\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/241
URL:https://www.pharmaconomics.com/e/241
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RCKT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR